Press releases
Find out more about Ferring latest announcements.
Press releases
-
Ferring to Present Award-Winning, Landmark Research for Investigational Microbiota-Based Live Biotherapeutic RBX2660 at IDWeek 2021
-Analysis of data from five RBX2660 prospective studies is one of only four abstracts to receive the coveted IDWeek 2021 Program Committee Choice award for outstanding scientific research. Ferring and Rebiotix will present new data showing an association between clinical outcomes and restoration of the microbiome. Research from the Phase 3 PUNCH CD3 trial on the effects of RBX2660 on […]
-
Fertility House Calls Now Available Nationwide to Help Women and Couples Take the First Steps to Parenthood Virtually
-Fertility House Calls connects women and couples with personalized fertility care from the comfort of their own home. Service designed to reduce the emotional burden associated with the fertility journey Parsippany, NJ – September 15, 2021 – Ferring Pharmaceuticals announced today the expansion of Fertility House Calls—a platform that connects women and couples with fertility specialists for an initial virtual […]
-
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW)
-Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile ( difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeutic Expanded inclusion criteria allowed for enrollment of patients with C. difficile infection typically seen in clinical […]